ACR TI-RADS评分越高是否预示恶性风险增加?ACR TI-RADS与FNA细胞学相关性研究
该研究评估ACR TI-RADS超声评分与FNA细胞学Bethesda诊断的相关性。2018年1月1日至8月30日共2306例甲状腺超声引导FNA,其中361例有ACR TI-RADS报告。多数FNA为TR4(180;49.9%)或TR3(108;29.9%);无TR2或TR3结节伴Bethesda V或VI诊断;TR4中78.9%(142/180)和TR5中64.6%(42/65)为良性(Bethesda II);14例TR5(21.5%)为恶性(Bethesda VI)。结论认为ACR TI-RADS评分系统与良恶性细胞学诊断至少存在一定相关性。
要点
- TR2或TR3结节未出现Bethesda V或VI诊断。
- TR4结节多数(78.9%)为Bethesda II良性细胞学。
- TR5结节中21.5%为Bethesda VI恶性细胞学。
核心结论
- ACR TI-RADS评分系统与FNA细胞学良恶性诊断至少存在一定相关性,高级别TR类别中恶性病例更多。
研究设计与样本
- 回顾性评估2018年1月1日至8月30日ACR TI-RADS超声报告及对应FNA细胞学诊断。
- 共2306例甲状腺超声引导FNA,其中361例有ACR TI-RADS报告。
主要发现
- 多数FNA为TR4(180;49.9%)或TR3(108;29.9%)。
- 无TR2或TR3结节伴Bethesda V或VI诊断。
- TR4结节中142/180(78.9%)为良性(Bethesda II)。
- TR5结节中42/65(64.6%)为良性(Bethesda II)。
- 14例TR5(21.5%)为恶性(Bethesda VI)。
临床怎么用
- ACR TI-RADS评分可辅助预测甲状腺结节恶性概率,高级别TR类别应结合FNA细胞学进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrasound has become the initial approach to evaluating thyroid nodules, facilitating the distinction between benign and malignant nodules based on composition, echogenicity, nodule border or margin, shape, the presence of calcifications, and nodule dimensions. The American College of Radiology (ACR) recommended the Thyroid Imaging Reporting and Data System (TI-RADS) as a classification system to standardize thyroid ultrasound reports and to predict the probability of malignancy in thyroid nodules using a scoring system (TR1-TR5) based on multiple ultrasound characteristics and nodule size. Fine-needle aspiration (FNA) is recommended as the next step for nodules that warrant further workup. The authors assessed the accuracy of the ACR TI-RADS based on the corresponding FNA cytology results (Bethesda system diagnoses I-VI). METHODS: ACR TI-RADS ultrasound reports and corresponding FNA cytology diagnoses from January 1, 2018 to August 30, 2018 were evaluated. RESULTS: From January 1, 2018 to August 30, 2018, 2306 thyroid ultrasound-guided FNAs were performed at our institution. Of 2306 cases, 361 had ACR TI-RADS reports available. The majority of FNAs were TR4 (180; 49.9%) or TR3 (108; 29.9%). No TR2 or TR3 nodules were associated with Bethesda category V or VI diagnoses. The majority of TR4 nodules (142 of 180; 78.9%) and TR5 nodules (42 of 65; 64.6%) exhibited benign (Bethesda category II) cytology. Fourteen TR5 cases (21.5%) had malignant (Bethesda category VI) cytology. CONCLUSIONS: Although there were no TR2 or TR3 malignant (Bethesda category VI) diagnoses, and there were only a few malignancies in the TR4 and TR5 categories, the current results reassert the notion that the ACR TI-RADS scoring system shows at least some correlation between benign or malignant cytology diagnoses, as illustrated by the greater number of malignant cases in the higher ACR TI-RADS categories.
引用
- Modi L, Sun W, Shafizadeh N, et al. Does a higher American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) score forecast an increased risk of malignancy? A correlation study of ACR TI-RADS with FNA cytology in the evaluation of thyroid nodules. Cancer Cytopathol. 2020. PMID: 32078249. doi:10.1002/cncy.22254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。